3,7-dioxolanosta-8,24-dien-26-oic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,7-dioxolanosta-8,24-dien-26-oic acid: isolated from the mushroom Ganoderma lucidum [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	46888220
CHEMBL ID	1099224
MeSH ID	M0588848
PubMed CID	72787537
MeSH ID	M0588848

Synonyms (9)

Synonym
173075-45-1
CHEMBL1099224
ganoderic acid dm
bdbm50104745
AKOS032948636
(z,6r)-2-methyl-6-[(5r,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-3,7-dioxo-2,5,6,11,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]hept-2-enoic acid
3,7-dioxolanosta-8,24-dien-26-oic acid
BCP16405
gaderic acid dm

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay ID	Title	Year	Journal	Article
AID353555	Inhibition of 5-alpha-reductase in rat liver microsome assessed as conversion of [14C] testosterone to [14C] dihydrotestosterone	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID1235935	Cytotoxicity against human PC3 cells by MTT method	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID353564	Cytotoxicity against mouse RAW264 cells assessed as viable cells at 25 uM after 3 days by WST1 assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID1235933	Inhibition of maltase in rat intestinal mucosa pre-incubated for 40 mins using maltose substrate	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1551897	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by WST-1 assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y.
AID353557	Growth inhibition against testosterone-induced human LNCAP cell proliferation assessed as decrease in cell viability after 3 dayssby NR assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID1235931	Inhibition of alpha-glucosidase in rat intestinal mucosa pre-incubated for 40 mins using p-nitrophenyl-alpha-D-glucopyranoside substrate	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1235929	Inhibition of pig liver microsomes HMG-CoA reductase incubated for 5 mins in using HMG-CoA and NADPH by colorimetric method	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1235932	Inhibition of sucrase in rat intestinal mucosa pre-incubated for 40 mins using sucrose substrate	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1551899	Inhibition of calcitriol-induced formation of Sprague-Dawley rat osteoclasts by WST-1 assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y.
AID353562	Inhibition of osteoclastogenesis in RANKL-stimulated mouse RAW264 cells at 25 uM after 3 days by TRAP assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID1235934	Cytotoxicity against human K562 cells by MTT method	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID711425	Inhibition of rat microsomal 5-alpha reductase assessed as inhibition of conversion of [4-14C]testosterone to [4-14C] dihydrotestosterone after 10 mins	2012	Journal of natural products, Nov-26, Volume: 75, Issue:11	Lanostanoids from fungi: a group of potential anticancer compounds.
AID353554	Inhibition of DHT binding to human recombinant androgen receptor ligand binding domain at 15 uM by fluorescence polarization	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID1235930	Inhibition of Baker's yeast alpha-glucosidase	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID353559	Antiproliferative activity against human PC3 cells at 12.5 to 50 uM after 3 days by NR assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID1551898	Inhibition of RANKL/tumour necrosis factor alpha-induced formation of osteoclasts (unknown origin) by tartrate-resistant acid phosphatase staining based assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y.
AID353563	Cytotoxicity against mouse RAW264 cells assessed as cell number at 12.5 uM after 3 days by WST1 assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID353556	Growth inhibition of human LNCAP cells assessed as decrease in cell viability after 3 days by NR assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID353561	Inhibition of osteoclastogenesis in RANKL-stimulated mouse RAW264 cells at 12.5 uM after 3 days by TRAP assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID479066	Antiplasmodial activity against Plasmodium falciparum at 20 uM	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Antiplasmodial lanostanes from the Ganoderma lucidum mushroom.
AID711441	Cytotoxicity against human HeLa cells	2012	Journal of natural products, Nov-26, Volume: 75, Issue:11	Lanostanoids from fungi: a group of potential anticancer compounds.
AID353558	Growth inhibition against dihydrotestosterone-induced human LNCAP cell proliferation assessed as decrease in cell viability after 3 dayssby NR assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (9.09)	18.2507
2000's	1 (9.09)	29.6817
2010's	7 (63.64)	24.3611
2020's	2 (18.18)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.84 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.63 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	2 (40.00%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	3 (60.00%)	84.16%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.11	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.17	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.05	1	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
atorvastatin [no description available]	2.11	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
eburicoic acid eburicoic acid: structure	3.17	1
10-hydroxycamptothecin [no description available]	3.17	1	pyranoindolizinoquinoline
acarbose [no description available]	2.11	1	amino cyclitol; glycoside
ganoderic acid a [no description available]	4.13	2	triterpenoid
ganoderiol f ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source	3.59	2	triterpenoid
Ganodermanontriol [no description available]	3.59	2	triterpenoid	metabolite
alpha-linolenic acid linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.	2.05	1	linolenic acid; omega-3 fatty acid	micronutrient; mouse metabolite; nutraceutical
poricoic acid g poricoic acid G: from Poria cocos (Polyporaceae); structure in first source. poricoic acid G : A tricyclic triterpenoid isolated from Poria cocos.	3.17	1	dicarboxylic acid; secondary alcohol; tricyclic triterpenoid	fungal metabolite
polyporenic acid c [no description available]	3.17	1
trametenolic acid b trametenolic acid B: from Trametes lactinea; structure in first source	3.17	1	triterpenoid
ganodermadiol ganodermadiol: isolated from Ganoderma lucidum; structure given in first source. ganoderol B : A tetracyclic triterpenoid that is lanosta-7,9(11),24-triene which is substituted by hydroxy groups at positions 3 and 27. It has been isolated from several Ganoderma species.	3.86	3	3beta-sterol; primary allylic alcohol; tetracyclic triterpenoid	antiviral agent; fungal metabolite; hepatoprotective agent
lucidenic acid a lucidenic acid A: isolated from fruiting bodies of Ganoderma lucidum; structure in first source	3.17	1	triterpenoid
ganoderic acid t ganoderic acid T: down-regulates expression of both MMP-2 and MMP-9; isolated from Ganoderma lucidum; structure in first source	3.17	1
ganoderic acid f ganoderic acid F: isolated from Ganoderma lucidum; structure in first source	3.17	1	triterpenoid
inotodiol inotodiol: structure in first source	3.17	1
ganoderic acid c2 ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source	4.13	2	triterpenoid
ganoderic acid y ganoderic acid Y: has antiviral activity; isolated from Ganoderma lucidum; structure in first source	4.42	3	triterpenoid
7-oxo-ganoderic acid z 7-oxo-ganoderic acid Z: from the mushroom Ganoderma lucidum; structure in first source	3.59	2
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.25	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
tangeretin tangeretin: structure given in first source; from citrus plants; inhibits invasion of MO4 mouse cells into embryonic chick heart in vitro. tangeretin : A pentamethoxyflavone flavone with methoxy groups at positions 4', 5, 6 , 7 and 8.. pentamethoxyflavone : A methoxyflavone that is flavone substituted by a five methoxy groups.	2.11	1	pentamethoxyflavone	antineoplastic agent; plant metabolite
limonin [no description available]	2.11	1	epoxide; furans; hexacyclic triterpenoid; lactone; limonoid; organic heterohexacyclic compound	inhibitor; metabolite; volatile oil component
lanosterol [no description available]	2.75	3	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
gingerol gingerol: an active ingredient in GINGER along with SHOGAOL. a nonvolatile methoxy phenyl decanone. gingerol : A beta-hydroxy ketone that is 5-hydroxydecan-3-one substituted by a 4-hydroxy-3-methoxyphenyl moiety at position 1; believed to inhibit adipogenesis. It is a constituent of fresh ginger.	2.11	1	beta-hydroxy ketone; guaiacols	antineoplastic agent; plant metabolite
decitabine [no description available]	2.25	1	2'-deoxyribonucleoside
sesquiterpenes [no description available]	2.11	1
zerumbone zerumbone: RN given for (E,E,E)-isomer; structure in first source. zerumbone : A sesquiterpenoid and cyclic ketone that is (1E,4E,8E)-alpha-humulene which is substituted by an oxo group at the carbon atom attached to two double bonds. It is obtained by steam distillation from a type of edible ginger, Zingiber zerumbet Smith, grown particularly in southeast Asia.	2.11	1	cyclic ketone; sesquiterpenoid	anti-inflammatory agent; glioma-associated oncogene inhibitor; plant metabolite
ganodermic acid s ganodermic acid S: RN given refers to (3beta,15alpha,24E)-isomer	1.99	1	triterpenoid
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	2.21	1
ganoderic acid a ganoderic acid A: isolated from Ganoderma lucidum; structure in first source	2.57	2

Condition	Relationship Strength	Studies
Plasmodium falciparum Malaria [description not available]	2.05	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.05	1
Anaplasia Loss of structural differentiation and useful function of neoplastic cells.	2.25	1
Benign Meningeal Neoplasms [description not available]	2.25	1
Angioblastic Meningioma [description not available]	2.57	2
Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.	2.25	1
Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)	2.57	2
Carcinoma, Non-Small Cell Lung [description not available]	2.25	1
Cancer of Lung [description not available]	2.25	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.25	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.25	1
Cancer of Prostate [description not available]	2.21	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.21	1
Malignant Melanoma [description not available]	2.07	1
B16 Melanoma [description not available]	2.07	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.07	1

chemdatabank.com